Quantcast
Channel: Market Playground » pipeline
Browsing latest articles
Browse All 25 View Live

Stock Brief: TrovaGene (NASDAQ:TROV) Trades Solidly Above $7.00 On Big...

By VFC’s Stock House TrovaGene Inc. (NASDAQ:TROV) shares closed last week on another high note when double-the-average volume resulted in a ten percent gain for the stock. Another spike earlier on...

View Article



Oversold Now After Earlier Spikes, These Stocks Could Offer Solid Upside in...

By Sven Olson Time can be an investor’s best tool, but it cannot be controlled…only utilized to his/her advantage. One such way to use time to your benefit as an investor is to come to the simple...

View Article

Three Biopharmaceutical Companies with Promising Cancer Therapies in Late...

By The Swiss Trader For 2012 the broader biotech indices, the NASDAQ Biotechnology Index (NBI) was up more than 30%, almost double the 15.9% rise in the S&P 500. The NBI has 117 companies, but...

View Article

Weekly Stock Watch for the Week of January 14th, 2013

By VFC’s Stock House The trading year of 2013 kicks off in a big way this week. Although the markets rallied for the first couple of weeks of the year, the noted price and mood fluctuations were based...

View Article

Portfolio Moves with Gabriel Grego: SNY, TOT, HAL, NOV, WU, NLY, TEVA

By Gabriel Grego It’s been another turbulent year for the world economy, but overall we believe we can look back at the year 2012 with a smile and reasonable confidence for the future. The year started...

View Article


Stock Watch for Wednesday, January 16th, 2013: FB, GOOG, BA, GS, JPM, IRWD,...

By VFC’s Stock House Markets traded modestly higher for the day on Tuesday as retail sales numbers came in better than expected for the month of December, easing worries created late last year of a...

View Article

Retrophin (RTRX) Is Worth A Look

By Spencer Osborne Retrophin (PINK:RTRX), a pharmaceutical start-up, is building a business in an otherwise competitive sector by focusing on a sub-category called orphan drugs. An orphan drug is one...

View Article

Devon Energy Corporation (NYSE:DVN): Buy, Sell or Hold?

By Sven Olson When U.S. natural gas producers release their 2012 annual reports, many companies may have to reduce a key indicator of their financial health: Reserves. Even though U.S. natural gas...

View Article


Galena Biopharma’s (NASDAQ:GALE) Breast Cancer Vaccine Offers New Hope

By Amy Baldwin Galena Biopharma, Inc. (NASDAQ:GALE) is working on its breast cancer vaccine, NeuVax, which has entered into Phase III trials. If successful, this vaccine would not only help prevent...

View Article


Four Small Biotechs with Big Potential in 2013

By The Swiss Trader It’s easy to look towards the large biotech companies for catalysts in a given year. However, there is often more upside lingering in the smaller names that have data on the...

View Article

New Age Diversification with the $50,000 Portfolio (CVX, VZ, LO, BBT, F,...

By Brian Nichols The primary goal of diversification has always been quite clear: It is to invest in a number of sectors, markets, and types of investments to be better protected from volatility and to...

View Article

An Investor’s Guide to the Keystone XL Pipeline Saga: TRP, ENB, SU, CNQ, CVE,...

By Xavier Brenner The Obama Administration is chasing two policy goals that sometimes bang heads: energy independence from Mideast oil and curbing greenhouse gas emissions. That pretty much sums up the...

View Article

Three Microcap Movers: SPEX, CLSN, PLUG

By Robert Sutton While big name stocks such as Caterpillar Inc. (NYSE:CAT) and JPMorgan Chase & Co. (NYSE:JPM) traded higher on Wednesday, there were several microcap stocks that also saw huge...

View Article


Weekly Stock Watch: DIS, AMRN, TEVA, AZN, GSK, IMSC, FPMI, KERX, SNY, ANTB,...

By VFC’s Stock House This week could be a pivotal one. Record market highs are well within sight and investors will look for evidence that last week’s bullish momentum can continue into the new trading...

View Article

A Stem Cell Investment — Made Simple

By Teresa Dawn Albert Einstein famously said, “If you can’t explain it simply, then you don’t understand it well enough.” This quote could easily occur to an investor who wants to dive into the stem...

View Article


Investing in Companies Developing Natural Zero Calorie Sugar Substitutes...

By Henry Kawabe As consumers opt for a healthier alternative to sugar or high fructose corn syrup (HFCS), both large and small companies have been investing in developing various natural zero calorie...

View Article

Weekly Stock Watch: SNWV, SSH, FPMI, AA, WMT, PIR, BBBY, HTWR, THOR

By VFC’s Stock House As the broad market rally looks to have sputtered, and with the upcoming earnings season not expected to blow away estimates by any means, investors will be looking to bank profits...

View Article


Industry Trends May Be Shifting Towards Boutique Pharmacy Services: APHY,...

By VFC’s Stock House Discovering industry trends early and then establishing positions in companies who may benefit from those trends ahead of the general market could quickly turn into a successful...

View Article

Galena Biopharma Inc. (NASDAQ:GALE): Behind the Analyst Ratings

By Teresa Dawn Galena Biopharma’s (NASDAQ:GALE) share price has been climbing steadily since the new year — right along with its analyst ratings. Starting 2013 around $1.80, GALE is now trading...

View Article

SanuWave Health Inc. (SNWV) Boosts Long-Term Potential with Short-Term Catalysts

By VFC’s Stock House SANUWAVE Health Inc. (OTC:SNWV), with trial catalysts pending over the near term, has received its fair share of attention during the course of 2013 thus far, but the company’s...

View Article

Don’t Let These Five Speculative Stock Plays Slip Below The Radar: FPMI,...

By VFC’s Stock House On numerous occasions during the record-breaking rally of 2013 we’ve pointed out the fact that the more speculative and ‘under the radar’ sectors of the investing world are often...

View Article


Specialty Pharmacies Offer Solutions — Also For Investors: PMC, BIOS, APHY

By Dutch Trader In 2012, Americans filled more than 4 billion prescriptions at 62,000 retail, mail, and specialty pharmacies. The largest U.S. pharmacies ranked by total prescription you will find in...

View Article


Interesting Immunotherapy Cancer Stocks: AMGN, ONCS, VICL

By Stone Fox Capital Advisors As with any treatments dealing with cancer, opportunity exists to drastically improve the survival rates and, as importantly, reduce the side effects caused by surgery and...

View Article

NeoStem Inc. (NYSEMKT:NBS): On the Leading Edge of the Advancement of Cell...

By Craig Keolanui  Is stem cell therapy going to be to the biotechnology industry what Tesla Motors is to the automotive industry? Stem cell therapy has waited at the sidelines while investors pump...

View Article

OncoSec Medical Inc. (OTCMKTS:ONCS): A Presentation Of Catalysts

By Arthur Rhodes The Rodman & Renshaw Investment Conference this week highlighted several of biotechnology’s most exciting companies such as Verastem Inc. (NASDAQ:VSTM), Keryx Biopharmaceuticals...

View Article

Browsing latest articles
Browse All 25 View Live




Latest Images